<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Braz J Med Biol Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Braz. J. Med. Biol. Res</journal-id>
      <journal-title-group>
        <journal-title>Brazilian Journal of Medical and Biological Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0100-879X</issn>
      <issn pub-type="epub">1414-431X</issn>
      <publisher>
        <publisher-name>Associa&#xE7;&#xE3;o Brasileira de Divulga&#xE7;&#xE3;o Cient&#xED;fica</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26017341</article-id>
      <article-id pub-id-type="pmc">4512095</article-id>
      <article-id pub-id-type="doi">10.1590/1414-431X20154557</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Biomedical Sciences</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evaluation of a father and son with atypical chronic myeloid leukemia
with <italic>SETBP1</italic> mutations and a review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Du</surname>
            <given-names>F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>H.-M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>H.-X.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Hematology, The Central Hospital of Wuhan, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan, China</aff>
      <aff id="aff2"><label>2</label>Department of Gastroenterology, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China</aff>
      <author-notes>
        <corresp>Correspondence: Hong-xiang Wang: <email>397959379@qq.com</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <volume>48</volume>
      <issue>7</issue>
      <fpage>583</fpage>
      <lpage>587</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report the case of a father and son diagnosed with atypical chronic myeloid
leukemia (aCML). Both patients harbored <italic>SETBP1</italic> mutations, which are
present in 24.3% of aCML patients. Moreover, both shared the variant encoding
p.Pro737His, but the aCML severity was greater in the son because of the presence of
two other missense mutations causing p.Asp868Asn and p.Ser885Arg alterations.
<italic>SETBP1</italic> mutations may be associated with an adverse prognosis, so
their detection would help in the diagnosis of aCML and the determination of a
patient's prognosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Atypical chronic myeloid leukemia</kwd>
        <kwd><italic>SETBP1</italic> mutation</kwd>
        <kwd>Chronic neutrophilic leukemia</kwd>
        <kwd><italic>CSF3R</italic> mutation</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="15"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Atypical chronic myeloid leukemia (aCML), a rare disorder of hematopoietic stem cells,
has both myelodysplastic and myeloproliferative characteristics and is classified as an
example of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) according to the World
Health Organization (WHO) classification system (<xref rid="B01" ref-type="bibr">1</xref>). aCML shares clinical and laboratory features with CML, but lacks the
<italic>BCR-ABL</italic> fusion gene.</p>
      <p>
<italic>SETBP1</italic> encodes SET-binding protein 1, a binding partner for the
multi-functional SET protein, which is involved in apoptosis, transcription, and
nucleosome assembly. A 2013 analysis of exome sequences from 8 aCML cases led to the
identification of recurrent <italic>SETBP1</italic> somatic mutations; then targeted
resequencing demonstrated the <italic>SETBP1</italic> mutations were present in 24.3% of
70 patients with aCML, as well as in the closely related disorders unclassified MDS/MPN
(3/30, 10%) and chronic myelomonocytic leukemia (CMML; 3/82, 4%), and in one of four
cases of chronic neutrophilic leukemia (CNL) (<xref rid="B02" ref-type="bibr">2</xref>).
Among these diseases, CNL was relatively difficult to differentiate from aCML until
2013, because the diagnosis of both diseases required the exclusion of other hematologic
neoplasms, as molecularly defined in the WHO Classification of Myeloid Disorders (<xref rid="B01" ref-type="bibr">1</xref>). Recently, this situation was resolved because
WHO-defined CNL has been shown to be associated with mutations in the gene encoding
colony-stimulating factor 3 receptor (<italic>CSF3R</italic>), most commonly
<italic>CSF3R</italic> T618I (<xref rid="B03" ref-type="bibr">3</xref>&#x2013;<xref rid="B06" ref-type="bibr">6</xref>).</p>
      <p>Here, we report two cases of aCML with <italic>SETBP1</italic> mutations in a father and
his son.</p>
    </sec>
    <sec>
      <title>Case description</title>
      <p>The 30-year-old son was admitted to our hospital on July 2, 2013, because of an enlarged
spleen with a maximum thickness of 9.6 cm. His peripheral blood count status was: white
blood cells (WBCs), 16.75&#xD7;10<sup>9</sup>/L; hemoglobin, 8.4 g/dL; and platelets,
620&#xD7;10<sup>9</sup>/L. Bone marrow aspiration revealed hypercellularity, different
cell body sizes, diminished or moderate cytoplasms, round or oval nuclei, enhanced
nuclear chromatin, and 10% myeloblasts. Differential flow cytometric analysis
demonstrated that the blasts expressed the myeloid antigens CD34, CD13, and CD117. A
bone marrow biopsy showed a small amount of fibroblast proliferation (<xref ref-type="fig" rid="f01">Figure 1</xref>), and conventional chromosomal analysis
revealed a normal karyotype (46, XY). Further analysis indicated that
<italic>BCR/ABL</italic>, <italic>JAK2</italic> 617F, <italic>JAK2</italic> exon 12,
<italic>FIP1L1/PDGFA</italic>, <italic>ETV6-PDGFRB</italic>, <italic>MPL</italic>
W515L/K, and c-kit/D816V mutations were absent. However, a <italic>SETBP1</italic>
mutation was detected in a SKI homologous region (amino acids 706-917) in the bone
marrow sample.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Bone marrow smear and biopsy of the son. <italic>A</italic>, Bone marrow smear
stained with Wright-Giemsa (original magnification, 1000&#xD7;). Black arrow:
myeloblast (July 2013). <italic>B</italic>, Bone marrow biopsy stained with
hematoxylin and eosin (original magnification, 100&#xD7;). White arrow: fibroblast
proliferation (July 2013).</title>
        </caption>
        <graphic xlink:href="1414-431X-bjmbr-48-07-00583-gf01"/>
      </fig>
      <p>PCR and Sanger sequencing to screen for <italic>SETBP1</italic> mutations (using primer
pairs primer 1, forward: <named-content content-type="gene">5'-GTTGCTCTGAAGGCAAAAGC-3'</named-content> and reverse: <named-content content-type="gene">5'-GTTGTTGTCTGTCCCAATGC-3'</named-content>, and primer 2,
forward: <named-content content-type="gene">5'-GAAGCTGTCTCCACCCAGAC-3'</named-content>
and reverse: <named-content content-type="gene">5'-AGAGCAACGGGTCATACTGG-3'</named-content>) identified three missense mutations
causing p.Pro737His, p.Asp868Asn, and p.Ser885Arg alterations (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>
<italic>SETBP1</italic> mutations (boxed) present in the son
(<italic>A</italic>-<italic>C</italic>) and the father (<italic>D</italic>).
Upper rows indicate normal sequences, and lower rows indicate patient
sequences.</title>
        </caption>
        <graphic xlink:href="1414-431X-bjmbr-48-07-00583-gf02"/>
      </fig>
      <p>A low dose of cytarabine (30 mg/day) was administered for 14 days each month beginning
July 11, 2013, and interferon &#x3B1;-2a (300 MU) was administered three times weekly by
subcutaneous injection but was discontinued because of intolerance after several
administrations. However, no significant improvement in fatigue, spleen size, or bone
marrow blasts occurred, and the patient suffered aggravated anemia and persistent fever
while being treated with antibiotics. On September 13, 2013, the patient began treatment
with imatinib mesylate (400 mg/day) (<xref rid="B07" ref-type="bibr">7</xref>), which
was withdrawn 1 month later and followed by intermittent treatment with cyclophosphamide
and hydroxyurea. On November 19, 2013, an ultrasound revealed that the patient&#x2019;s liver
and spleen had further increased in size, and that both of their inferior borders were
located in the pelvic cavity. The peripheral blood count status was: WBCs,
136&#xD7;10<sup>9</sup>/L; hemoglobin, 5.0 g/dL; and platelets, 705&#xD7;10<sup>9</sup>/L. On
December 2, 2013, the patient died from respiratory failure.</p>
      <p>The patient&#x2019;s father was 59 years old in July 2008 when he was diagnosed with aCML. He
presented with a giant spleen and the following peripheral blood count status: WBCs,
34.54&#xD7;10<sup>9</sup>/L; hemoglobin, 115 g/dL; and platelets, 1190&#xD7;10<sup>9</sup>/L.
Ultrasonography and computerized tomography demonstrated a normal liver but an enlarged
spleen with a maximum thickness of 8.3 cm, and 7.4 cm under the left rib cage. Tests for
BCR/ABL JAK2 617F and CSF3R mutations were negative, although the bone marrow smear and
biopsy were indicative of aCML. He was treated with interferon &#x3B1;-2a (3.0 MU/day) plus
low-dose cytarabine (20 mg/m<sup>2</sup> during days 1-10) for approximately 4 months.
The regimen was voluntarily discontinued after the symptoms and peripheral blood count
status improved. In August 2013, the father was alive and stable, with no indication of
disease progression such as fever, anemia, increased blasts, or an enlarged spleen.
Analysis of <italic>SETBP1</italic> mutations in DNA from peripheral blood revealed the
presence of the variant encoding p.Pro737His, which was shared with his son (<xref ref-type="fig" rid="f02">Figure 2</xref>). No <italic>SETBP1</italic> mutations were
detected in the mother. The father died of cerebral infarction in August 2014.</p>
      <sec>
        <title>Compliance with ethics guidelines</title>
        <p>All procedures were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000 (<xref rid="B05" ref-type="bibr">5</xref>).
Written informed consent was obtained from all patients included in the study.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>In 2010, <italic>SETBP1</italic> mutations were identified as causative in the rare,
lethal disorder Schinzel-Giedion syndrome (<xref rid="B08" ref-type="bibr">8</xref>).
Recently, <italic>SETBP1</italic> mutations have also been identified in aCML and other
closely related hematological malignancies, including CNL, CMML, unclassified MDS, MPNs,
and secondary AML evolving from MDS at variable frequencies (1.7-25%) (<xref rid="B09" ref-type="bibr">9</xref>-<xref rid="B13" ref-type="bibr">13</xref>), as
shown in <xref ref-type="table" rid="t01">Table 1</xref>. Piazza et al. (<xref rid="B01" ref-type="bibr">1</xref>) reported that aCML patients with
<italic>SETBPI</italic> mutations had a worse prognosis (median survival, 22 versus
77 months) and presented with higher WBC counts at the time of diagnosis (median, 81.0
versus 38.5&#xD7;10<sup>9</sup>/L) compared with aCML cases with wild-type
<italic>SETBP1</italic>. Another team showed that <italic>SETBP1</italic>mutations
often co-occurred with cytogenetic markers such as -7/del(7q) and i(17)(q10), which were
associated with a reduced overall survival time and an increased risk of leukemic
evolution from MDS (<xref rid="B14" ref-type="bibr">14</xref>).</p>
      <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Incidence of SETBP1 mutations in hematological diseases, as reported in the
literature.</title></caption><graphic xlink:href="1414-431X-bjmbr-48-07-00583-gt01"/></table-wrap>
</p>
      <p>However, the presence of <italic>SETBP1</italic> mutations was ineffective at
differentiating aCML from CNL. <italic>CSF3R</italic> encodes the cell surface
transmembrane receptor for granulocyte colony stimulating factor, which induces the
proliferation, differentiation, and survival of myeloid progenitors. In 2013, Maxson et
al. (<xref rid="B03" ref-type="bibr">3</xref>) reported frequent <italic>CSF3R</italic>
mutations in patients with CNL (8/9, 88.9%) and aCML (8/18, 44.4%). Two types of
<italic>CSF3R</italic> mutation were found: T618I (n=12) and T615A (n=2), which are
both located in the membrane proximal region that mediates proliferative and survival
signals. Pardanani et al. (<xref rid="B04" ref-type="bibr">4</xref>) performed
<italic>CSF3R</italic> mutation analysis on 54 patients with clinically suspected CNL
(n=35) or aCML (n=19). A central pathology review identified 12 WHO-defined CNL and 9
WHO-defined aCML patients. <italic>CSF3R</italic> T618I mutations were observed in 10
WHO-defined CNL cases, at a mutational frequency of 83% (10/12), and were not seen in
WHO-defined aCML, PMF (n=76), or CMML (n=94) cases. A further 3 non-CNL cases also
harbored <italic>CSF3R</italic> mutations.</p>
      <p>Together, these findings ensure that the diagnosis of CNL is no longer only one of
exclusion, and revision of the current WHO diagnostic criteria is expected to include
the molecular criterion of <italic>CSF3R</italic> mutation positivity (<xref rid="B15" ref-type="bibr">15</xref>). In 2014, Tefferi et al. (<xref rid="B05" ref-type="bibr">5</xref>,<xref rid="B06" ref-type="bibr">6</xref>) proposed a revision of
the WHO criteria, which included major and minor changes in the diagnosis of CNL, such
as <italic>i</italic>) a peripheral blood leukocyte level &#x2265;13&#xD7;10<sup>9</sup>/L,
<italic>ii</italic>) a peripheral blood neutrophil/band percentage distribution
&gt;80%, and <italic>iii</italic>) the presence of a <italic>CSF3R</italic> T618I
mutation or other membrane proximal <italic>CSF3R</italic> mutation. Therefore, although
most CNL patients carry <italic>SETBP1</italic> and <italic>ASXL1</italic> mutations,
which can also be detected in aCML, <italic>CSF3R</italic> mutations, particularly
<italic>CSF3R</italic> T618I, can be used to differentiate them.</p>
      <p>In the present cases, we demonstrated that <italic>SETBP1</italic> mutations can
co-occur in a father and son with aCML, but it remains to be determined whether these
were inherited or acquired. The detection of <italic>SETBP1</italic> and
<italic>CSF3R</italic> mutations will play an important role in diagnosing aCML, CNL,
and CMML patients, and determining their prognoses. These molecular markers are likely
to be incorporated into new diagnostic criteria soon.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other">
        <p>First published online.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vardiman</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arber</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Brunning</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Borowitz</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Porwit</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The 2008 revision of the World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia: rationale and important
changes</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>937</fpage>
          <lpage>951</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-03-209262</pub-id>
          <pub-id pub-id-type="pmid">19357394</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piazza</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Valletta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Winkelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Redaelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spinelli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pirola</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recurrent SETBP1 mutations in atypical chronic myeloid
leukemia</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>18</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.2495</pub-id>
          <pub-id pub-id-type="pmid">23222956</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maxson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gotlib</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pollyea</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Fleischman</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eide</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oncogenic CSF3R mutations in chronic neutrophilic
leukemia and atypical CML</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <fpage>1781</fpage>
          <lpage>1790</lpage>
          <pub-id pub-id-type="doi">10.1056/nejmoa1214514</pub-id>
          <pub-id pub-id-type="pmid">23656643</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pardanani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lasho</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Laborde</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Knudson</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CSF3R T618I is a highly prevalent and specific mutation
in chronic neutrophilic leukemia</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1870</fpage>
          <lpage>1873</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.122</pub-id>
          <pub-id pub-id-type="pmid">23604229</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Chronic neutrophilic leukemia 2014: Update on diagnosis,
molecular genetics, and management</article-title>
          <source>Am J Hematol</source>
          <year>2014</year>
          <volume>89</volume>
          <fpage>651</fpage>
          <lpage>658</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.23667</pub-id>
          <pub-id pub-id-type="pmid">24845374</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pardanani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Chronic neutrophilic leukemia: novel mutations and their
impact on clinical practice</article-title>
          <source>Curr Opin Hematol</source>
          <year>2015</year>
          <volume>22</volume>
          <fpage>171</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1097/moh.0000000000000114</pub-id>
          <pub-id pub-id-type="pmid">25575036</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breccia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>De Propris</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Frustaci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alimena</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Atypical chronic myeloid leukaemia with CD117-positive
blast cells treated with imatinib: A report of two cases</article-title>
          <source>Acta Haematol</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>211</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="doi">10.1159/000094684</pub-id>
          <pub-id pub-id-type="pmid">17016042</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoischen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van Bon</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Gilissen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arts</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>van Lier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Steehouwer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo mutations of SETBP1 cause Schinzel-Giedion
syndrome</article-title>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>483</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.581</pub-id>
          <pub-id pub-id-type="pmid">20436468</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Damm</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Itzykson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kosmider</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Droin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Renneville</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chesnais</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SETBP1 mutations in 658 patients with myelodysplastic
syndromes, chronic myelomonocytic leukemia and secondary acute myeloid
leukemias</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1401</fpage>
          <lpage>1403</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.35</pub-id>
          <pub-id pub-id-type="pmid">23443343</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laborde</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Patnaik</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Lasho</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Finke</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Knudson</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SETBP1 mutations in 415 patients with primary
myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in
CMML</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>2100</fpage>
          <lpage>2102</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.97</pub-id>
          <pub-id pub-id-type="pmid">23558523</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thol</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Suchanek</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Koenecke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stadler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Platzbecker</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Thiede</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SETBP1 mutation analysis in 944 patients with MDS and
AML</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>2072</fpage>
          <lpage>2075</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.145</pub-id>
          <pub-id pub-id-type="pmid">23648668</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meggendorfer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bacher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Alpermann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Haferlach</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN
cases and are strongly associated with atypical CML, monosomy 7, isochromosome
i(17)(q10), ASXL1 and CBL mutations</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1852</fpage>
          <lpage>1860</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.133</pub-id>
          <pub-id pub-id-type="pmid">23628959</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Makishima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Przychodzen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sanada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okuno</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Somatic SETBP1 mutations in myeloid
malignancies</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>942</fpage>
          <lpage>946</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.2696</pub-id>
          <pub-id pub-id-type="pmid">23832012</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Mercado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pellagatti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Di Genua</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Larrayoz</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Winkelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Aranaz</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SETBP1 are recurrent in myelodysplastic
syndromes and often coexist with cytogenetic markers associated with disease
progression</article-title>
          <source>Br J Haematol</source>
          <year>2013</year>
          <volume>163</volume>
          <fpage>235</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.12491</pub-id>
          <pub-id pub-id-type="pmid">23889083</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The molecular genetics of chronic neutrophilic
leukaemia: defining a new era in diagnosis and therapy</article-title>
          <source>Curr Opin Hematol</source>
          <year>2014</year>
          <volume>21</volume>
          <fpage>148</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="doi">10.1097/moh.0000000000000014</pub-id>
          <pub-id pub-id-type="pmid">24335708</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
